[Evolution of the market of calcium dihydropyridinic antagonists and their use in the treatment of chronic forms of ischemic heart disease].
Modern calcium antagonists of the dihydropyridine series are indicated as treatment of stable angina of different functional classes to be used singly (monotherapy) or combined with other antiischemic drugs. The best option is to combine the above antagonists with beta-blockers. There are some restrictions in respect of only short-term-acting forms of nifedipine. Potential antiatherosclerotic properties of dihydropyridines have been shown in the experiment--these will, we believe, be corroborated in clinical settings.